PDE 7 Modulator Compounds for Selective T-Cell Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that effectively and selectively modulate PDE 7 activity to treat diseases and conditions related to T-cell activity, such as allergic diseases, inflammatory diseases, and immunological diseases.
Innovation Solution
The development of compounds, including pharmaceutically acceptable salts, stereoisomers, and prodrugs, that specifically modulate the activity of PDE 7 (e.g., PDE 7A, PDE 7B, or both), as represented by Structures (I) and (II), which are used in pharmaceutical compositions for various therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to selectively modulate PDE 7 activity, then therapeutic effectiveness for T-cell related diseases is improved, but compound specificity and selectivity become more difficult to achieve
Solution Approach 1:
The patent applies local quality by designing specific substituent patterns at defined positions on the core heterocyclic structure. Different substituents (R1-R6, R8-R13) are strategically placed to create localized interactions with PDE 7, enhancing selectivity while maintaining therapeutic effectiveness. This is evident in the detailed structural requirements for each substituent position to optimize binding affinity and selectivity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, ring structures, and spatial arrangements to optimize PDE 7 selectivity. The extensive exploration of different heterocyclic cores, substituent groups, and stereochemical configurations represents a systematic parameter optimization approach to achieve both specificity and therapeutic effectiveness.
2Adaptability or versatility
If a broad range of diseases are targeted for treatment, then versatility of the compound is improved, but the complexity of compound design and development increases
Solution Approach 1:
The patent achieves universality by designing a core compound structure that can treat multiple disease types through its selective PDE 7 modulation. The disclosed compounds are applicable to inflammatory diseases, immunological diseases, allergic diseases, and other conditions involving T-cell activity, demonstrating multi-functionality from a single molecular platform.
Solution Approach 2:
The patent applies segmentation by dividing the complex therapeutic target (PDE 7) into specific isoform components (PDE 7A and PDE 7B) and designing compounds that can selectively modulate these isoforms. This segmentation approach allows the invention to address multiple disease pathways while maintaining a unified compound design strategy.
Data Source
AI summary
Compounds having activity as modulators of phosphodiesterase 7 (PDE 7) are provided. The compounds have the following Structures (I) or (II):as a stereoisomer, enantiomer, or tautomer thereof or a mixture thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein each of R1, R2, R3, R4a, R4b, ring A, ring B, ring A′ and ring B′ (i.e., {circle around (A)}, {circle around (B)}, , and as shown in Structure (I) and (II), respectively) are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of phosphodiesterase 7 (PDE 7) are also provided.